After a long wait, the US Food and Drug Administration cleared Dexcom's G7 continuous glucose monitor and the company plans to launch it in the US in early 2023.
The clearance has been delayed multiple times, with the most recent delay caused by a change in the device’s software which saw the removal of a snooze function that let
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?